Riskpilot← Back to searchSign inGet full accessTruSight Diagnostics AB
ABActiveOrg 5593189102Östra Förstadsgatan 44Medical specialists activities · NACE 8622Est. 20210 employees
Revenue 2025
SEK 0
EBITDA margin
—
+96% vs 2024
Equity ratio
72.5%
Financial strength
Net profit 2025
SEK -12K
+95% vs 2024
| Revenue | SEK 0 | — |
| EBITDA | SEK -12K | +96% |
| Net profit | SEK -12K | +95% |
| Total assets | SEK 159K | -57% |
| Equity | SEK 115K | -65% |
| Employees | 0 | — |
Legal name
TruSight Diagnostics AB
Org number
5593189102
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
24 maj 2021
Share capital
SEK 25 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Registrerad särskild delgivningsmottagare saknas. Då minst halva antalet styrelseledamöter ska vara bosatta inom EES uppfyller företaget inte kravet på bosättning.
Company purpose
Bolaget ska bedriva konsulterande läkarverksamhet samt tillhandahålla konsulttjänster och utbildning inom radiologisk granskning samt därmed förenlig verksamhet.
Address
Östra Förstadsgatan 44
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 881 | 584 | 1 026 | 0 | 0 |
| Staff expenses | — | −775 | −710 | −237 | −0 |
| EBITDA | 871 | −215 | 283 | −260 | −12 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | 871 | −215 | 283 | −260 | −12 |
| Net financials | — | −0 | −1 | 3 | 0 |
| Profit before tax | 871 | −215 | 282 | −257 | −12 |
| Tax | −180 | — | −14 | — | — |
| Net profit | 691 | −215 | 267 | −257 | −12 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 874 | 466 | 673 | 366 | 159 |
| Equity | 716 | 317 | 584 | 327 | 115 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 157 | 150 | 89 | 39 | 44 |
| Total debt | 157 | 150 | 89 | 39 | 44 |
EBITDA margin
-1165800.0%
This company
15.8%
Market median
-7378581% vs market
20212025
Equity ratio
72.5%
This company
38.2%
Market median
+90% vs market
20212025
Return on equity
-10.1%
This company
18.4%
Market median
-155% vs market
20212025
Net profit margin
-1160300.0%
This company
8.1%
Market median
-14324791% vs market
20212025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212025
Debt / equity
0.38×
This company
0.62×
Market median
+39% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-05-01 – 2021-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of TruSight Diagnostics AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Matthew Aaron Halperin | Deputy Board Member | 0 companies |
| Sandra-Veronica Kapoun Halperin | Board of Directors | 0 companies |
| Matthew Aaron Halperin | Deputy Board Member | 0 companies |